You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ASPIRIN AND DIPYRIDAMOLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Aspirin And Dipyridamole, and what generic alternatives are available?

Aspirin And Dipyridamole is a drug marketed by Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Endo Operations, Glenmark Speclt, Micro Labs, Sandoz, Sun Pharm, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in ASPIRIN AND DIPYRIDAMOLE is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aspirin And Dipyridamole

A generic version of ASPIRIN AND DIPYRIDAMOLE was approved as aspirin; dipyridamole by BARR on August 14th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ASPIRIN AND DIPYRIDAMOLE?
  • What are the global sales for ASPIRIN AND DIPYRIDAMOLE?
  • What is Average Wholesale Price for ASPIRIN AND DIPYRIDAMOLE?
Summary for ASPIRIN AND DIPYRIDAMOLE
US Patents:0
Applicants:11
NDAs:11
Finished Product Suppliers / Packagers: 10
Clinical Trials: 25
What excipients (inactive ingredients) are in ASPIRIN AND DIPYRIDAMOLE?ASPIRIN AND DIPYRIDAMOLE excipients list
DailyMed Link:ASPIRIN AND DIPYRIDAMOLE at DailyMed
Drug patent expirations by year for ASPIRIN AND DIPYRIDAMOLE
Recent Clinical Trials for ASPIRIN AND DIPYRIDAMOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rutgers, The State University of New JerseyPhase 3
Ministry of Health, FrancePhase 3
University Hospital, LillePhase 3

See all ASPIRIN AND DIPYRIDAMOLE clinical trials

US Patents and Regulatory Information for ASPIRIN AND DIPYRIDAMOLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206392-001 Mar 8, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glenmark Speclt ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 210318-001 May 24, 2019 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Molecular ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 204552-001 Mar 20, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.